Table 2 Response to (R)-CHOP in DLBCL patients. The data is presented for the entire group and separately for patients afflicted with type 2 diabetes mellitus or heart failure.

From: Type 2 diabetes mellitus compromises the survival of diffuse large B-cell lymphoma patients treated with (R)-CHOP – the PLRG report

 

CR

PR

SD

PD

Total

343 (73.1%)

86 (18.3%)

12 (2.6%)

28 (6.0%)

DMT2 (n = 76)

57 (75%) p > 0.05

11 (14.5%) p > 0.05

3 (3.9%) p > 0.05

5 (6.6%) p > 0.05

Heart failure (=46)

31 (67.4%) p > 0.05

10 (21.7%) p > 0.05

2 (4.4%) p > 0.05

3 (6.5%) p > 0.05

Neither DMT2 nor HF (=373)

274 (73.5%)

69 (18.5%)

8 (2.1%)

22 (5.9%)

Back to article page